Novo Nordisk A/S: CagriSema demonstrated 23% weight loss in an open-label head-to-head REDEFINE 4 trial in people with obesity, the primary endpoint was not achieved

Novo Nordisk A/S: CagriSema demonstrated 23% weight loss... CagriSema achieved 23% weight loss after 84 weeks of treatmentCagriSema 2.4/2.4 mg did not meet the primary endpoint of showing non-inferiority on weight loss compared to tirzepatide 15 mg at 84 weeks1Additional trials are exploring the full weight loss potential of CagriSema, including higher-dose... CagriSema achieved 23% weight loss after 84 weeks of treatmentCagriSema 2.4/2.4 mg did not meet the primary endpoint of showing non-inferiority on weight loss compared to tirzepatide 15 mg at 84 weeks1Additional trials are exploring the full weight loss potential of CagriSema, including higher-dose combinations Bagsværd, Denmark, 23 February 2026 âEUR" Novo Nordisk today announced headline results from REDEFINE 4, an open-label phase 3 trial from the global REDEFINE clinical trial programme. REDEFIN Market Context Stock market movements reflect investor sentiment, corporate earnings, and macroeconomic conditions. Investors should conduct thorough research and consider long-term fundamentals when making investment decisions. Key Takeaways Analyze company fundamentals and market trends for informed decisions Stay informed about economic indicators and central bank policies Maintain diversification across sectors and asset classes Published: February 23, 2026 | Source: Yahoo Finance